

References

1. Naughton CA. Drug-induced nephrotoxicity. *Am Fam Physician*. 2008;78(6):743-750.
2. Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System: Data and Statistics. CDC; 2024. Accessed May 20, 2026. <https://www.cdc.gov/kidney-disease/php/data-research/index.html>
3. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. *Lancet*. 2021;398(10302):786-802. doi:10.1016/S0140-6736(21)00519-5
4. AMBOSS. Chronic kidney disease. AMBOSS Medical Knowledge Platform. Updated 2024. Accessed May 20, 2026. <https://next.amboss.com/us>
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int*. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018
6. AMBOSS. Polypharmacy in older adults. AMBOSS Medical Knowledge Platform. Updated 2024. Accessed May 20, 2026. <https://next.amboss.com/us>
7. American Academy of Family Physicians. 2024 AGS Beers Criteria selected table. *Am Fam Physician*. 2024;109(4):374.
8. Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. *Am Fam Physician*. 2007;75(10):1487-1496.
9. Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. *Adv Exp Med Biol*. 2019;1165:3-15. doi:10.1007/978-981-13-8871-2_1
10. Neves PDMM, Graciolli FG, dos Reis LM, et al. Management of elderly patients with chronic kidney disease. *J Clin Med*. 2025;14(3):787. doi:10.3390/jcm14030787
11. Levey AS, Grams ME, Inker LA. Uses of GFR and albuminuria level in acute and chronic kidney disease. *N Engl J Med*. 2022;386(22):2120-2128. doi:10.1056/NEJMra2201153
12. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. *Br J Clin Pharmacol*. 2004;57(1):6-14. doi:10.1046/j.1365-2125.2003.02007.x
13. 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. *J Am Geriatr Soc*. 2023;71(7):2052-2081. doi:10.1111/jgs.18372
14. Hilmer SN, Gnjjidic D. The anticholinergic burden: from research to practice. *Aust Prescr*. 2022;45(4):118-120. doi:10.18773/austprescr.2022.031

15. Bulum T. Nephroprotective properties of the glucose-dependent insulintropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. *Biomedicines*. 2022;10(10):2586. doi:10.3390/biomedicines10102586
16. Verdoodt A, Honore PM, Jacobs R, et al. Do statins induce or protect from acute kidney injury and chronic kidney disease: an update review in 2018. *J Transl Intern Med*. 2018;6(1):21-25. doi:10.2478/jtim-2018-0005
17. Mouheb A, Massy Z, Metzger M, et al. Anticholinergic Burden and Progression to Kidney Replacement Therapy. *Kid Intern Rep* 2026; 11
18. Choudhury D, Ahmed Z. Drug-induced nephrotoxicity. *Med Clin North Am*. 1997;81(3):705-717.
19. Grubbs V, Plantinga LC, Tuot DS, et al. Americans' use of dietary supplements that are potentially harmful in CKD. *Am J Kidney Dis*. 2013;61(5):739-747. doi:10.1053/j.ajkd.2012.12.018
20. Pitt B, Filippatos G, Agarwal R, et al. Cardiorenal benefits of finerenone: protecting kidney and heart. *Eur Heart J Cardiovasc Pharmacother*. 2023;9(1):58-67. doi:10.1093/ehjcvp/pvac058
21. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. *N Engl J Med*. 2023;388(2):117-127. doi:10.1056/NEJMoa2204233
22. American Diabetes Association Clinical Practice Committee. Chronic kidney disease and risk management: Standards of care in diabetes. *Diab Care*. 2026;49(Suppl_1):S246-S260. <https://doi.org/10.2337/dc26-S011>
23. DeBoer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) *Diab Care*. 2022;45(12):3075-3090. <https://doi.org/10.2337/dci22-0027>
24. Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metabol*. academic.oup.com/jcem/article/105/12/3613/5909161. Accessed 21 May 2026.
25. Sterns RH. NSAIDs: Electrolyte Complications. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. <https://www.uptodate.com/contents/nsaids-electrolyte-complications>